Performance filings with the US Securities and Exchange Commission (SEC) are instructive in more ways than one, as documents often reveal the state of a corporation’s liability and litigation threats. Such is the case with C.R. Bard Inc. (C.R. Bard), a noted manufacturer of inferior vena cava filters that has been targeted with a rash of IVC Filter lawsuits.
To that end, the manufacturer of the Bard G2 IVC filter noted in its most current Form 10-Q Report for the period ending September 30th that it was facing 1,055 lawsuits in various federal and state jurisdictions.You can also contact Bard IVC Filter Attorneys for IVC Filter Complications Lawsuits.
Bard IVC filter lawsuits came under the scrutiny of the Judicial Panel for Multi-District Litigation in August of last year, which proceeded to move over 1,000 lawsuits into the Bard MDL. It has been reported that another 50 cases are currently pending in several state courts, with another 40 claims which thus far have been threatened with litigation, but as of the close of September had not yet been filed.
C.R. Bard is one of the several manufacturers dealing with allegations of defective products after scores of inferior vena cava filter patients have alleged injury after struts inherent to the design of the removable filters have broken free, and have migrated along the inferior vena cava artery to the heart and other organs.
The IVC filter itself has, in some cases, migrated away from the insert point and caused injury to the patient, or put the patient within imminent danger should the filter, or any of its part, reach the heart or lungs.
Allegations persist that C.R. Bard allowed for the allegedly tried Bard Recovery IVC filter to remain on the market for a period of years – without an IVC filter recall – before introducing its successor, the Bard G2 IVC filter.
The more one digs into the IVC filter debacle, the more one understands the Catch 22 which appears to govern the presence of the small, spider-like devices designed as a hedge against the migration of possibly dangerous blood clots through the inferior vena cava vein, the major thoroughfare that carries blood up from the lower extremities, where blood clots can form.You can get more info on IVC filters by browsing bardfilterlawsuitcenter.com/.
For one, the inferior vena cava filter (IVC filter) is created to capture, or snag blood clots and keep them from migrating to the lungs. But IVC filters themselves have been known to become dislodged from their primary insertion point, and migrate. The resulting IVC filter migration can pose a host of risks to the patient. Struts have broken off and have been found to migrate to the heart, or become embedded in aortic tissue, or other organs.
IVC filters, including the Bard G2 IVC filter (lawsuits for which have been consolidated for multidistrict litigation in Phoenix), are used only as a last option when patients are found to be unable to tolerate blood thinners, or the threat of blood clots are so great that anti-coagulants are not enough to effectively ward against the formation of blood clots.
The blood clot itself can be deadly if allowed to move to the lungs. IVC filters, including the Bard IVC filter and those made by other companies including Cook Medical, are deployed in the inferior vena cava and designed to capture a migrating blood clot and hold it in place until the clot disappears gradually on its own.
The IVC filter is only meant as a brief response to a more immediate, and compelling blood clot risk. The overall risk to a patient’s health increases the longer an IVC filter is left in the patient’s body.